Mar 17, 2026· Comment from American Academy of Pediatrics· FDA-2025-D-3217-0030
Filed as an attachment.
FDANonrulemakingFDA-2025-D-3217
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability
RIN
—
Last modified
Jun 29, 2026
Comment window
closed 137d ago
American Academy of Pediatrics (AAP) filings
1
Activity
American Academy of Pediatrics (AAP) filed 1 comment on this docket between Mar 17, 2026 and Mar 17, 2026. 9 other organizations filed here. The comment window closed 137d ago.
What American Academy of Pediatrics (AAP) filed (1)
Abstract
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability
View on regulations.gov →Co-filers (9)
See everyone who commented →- American Academy of Pediatrics (AAP)THIS ORG1 filing · confidence 97%
- American Association for Cancer Researchtrade assoc.1 filing · confidence 85%
- CPAC Foundation Center for Regulatory Freedomtrade assoc.1 filing · confidence 85%
- Critical Path Institutetrade assoc.1 filing · confidence 85%
- Duke-Robert J. Margolis Institute for Health Policytrade assoc.1 filing · confidence 85%
- European Federation of Statisticians in the Pharmaceutical Industrytrade assoc.1 filing · confidence 85%
- Insmed Incorporatedunverified attribution1 filing · confidence 70%
- International Society of Pharmacoepidemiologytrade assoc.1 filing · confidence 85%
- Pediatric Inclusion Alliancetrade assoc.1 filing · confidence 85%
- Presentient Technologiesunverified attribution1 filing · confidence 70%